You are here

Article Text

Article menu

other Versions

Download PDFPDF
Molecules in pathogenesis
PTEN as a target in melanoma
  1. Furkan Akif Ince,
  2. Artur Shariev,
  3. Katie Dixon
  1. School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
  1. Correspondence to Dr Katie Dixon, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; katie.dixon{at}sydney.edu.au

Abstract

PTEN is a well-known tumour suppressor protein that is frequently found to be mutated, inactivated or deleted in a wide range of different cancers. Its tumour suppressive properties result predominantly from its inhibitory effects on the PI3K-AKT signalling pathway. In melanoma, numerous different PTEN mutations have been identified in both melanoma cell lines and melanoma tissue. A number of different molecules can act on PTEN to either promote its suppression of melanoma, while other molecules may antagonise PTEN to inhibit its mechanism of action against melanoma. This review will discuss how the interactions of PTEN with other molecules may have a positive or negative impact on melanoma pathogenesis, giving rise to the potential for PTEN-targeted therapies against melanoma.

  • MELANOMA
  • GENETICS
  • Melanocytes
  • Pathology, Molecular
  • SKIN

https://doi.org/10.1136/jclinpath-2021-208008

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Rizwana Afroz.

    • Contributors FAI wrote the first draft of the manuscript, contributed to the revision and figure preparation. AS contributed to drafting of the manuscript and edited drafts of the manuscript. KD oversaw the first draft, edited all versions and contributed to figure preparation.

    • Funding This work was funded by the Cancer Institute NSW (KD).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.